Kornimate/medical-research-clean huggingface dataset:
study of asthma adherence reminders

Conditions: Childhood Asthma

Summary: to determine whether electronic adherence monitoring with feedback and reminder alarms can improve adherence and health outcomes in childhood asthma.

this study will investigate whether adding an electronic adherence monitor to inhaled steroids, and feeding this information back to patients and families can improve adherence and outcomes in childhood asthma. the devices will also sound twice daily reminder alarms to act as direct medication prompts. this intervention will be compared to a control group in which adherence is monitored, but with no feedback or alarms.

Eligibility criteria:
inclusion criteria: * doctor diagnosed asthma. * on at least bts stage 2, which means they will be on regular inhaled steroids. * no change in regular asthma treatment in the last 1 month (on regular inhaled steroids, no change in steroid dose for 1 month, no change in add on therapy in the last month). * acq (asthma control questionnaire) score more than or equal to 1.5. * can speak and understand english. exclusion criteria: * bts stage 5 asthma (complex issues, too unstable). * recent changes to asthma treatment within the last month. (see above) * acq (asthma control questionnaire) score \< 1.5. * another chronic health condition (eg diabetes, congenital heart disease, cystic fibrosis). * can't speak or understand english.
satisfactory debulking prediction model for advanced ovarian cancer based on pet-ct image data

Conditions: Ovarian Cancer; Image; Predation

Summary: this project intends to conduct a multicenter retrospective study to evaluate the satisfactory reduction of advanced ovarian cancer using pet-ct images, and explore the correlation between molecular biological characteristics and clinical characteristics of ovarian cancer through high-throughput sequencing genomics combined with radiomics.

ovarian cancer is the gynecological malignant tumor with the highest fatality rate. more than 70% of patients are diagnosed with advanced stage, often involving various organs of the pelvis and abdomen, which increases the difficulty of surgical resection, and the 5-year survival rate is only 30%. surgical treatment is the cornerstone of the treatment of ovarian cancer, and whether it can achieve satisfactory tumor reduction is an important factor affecting the prognosis of ovarian cancer. at present, the methods used to evaluate whether satisfactory tumor reduction can be achieved include suidan score based on ct image and fagotti score based on laparoscopic exploration, but there are problems such as low sensitivity, poor specificity or strong subjectivity, and the efficiency of predicting satisfactory tumor reduction is only about 60%. in recent years, pet-ct has been widely used in tumor diagnosis. pet-ct combined with pet metabolic imaging technology and traditional ct scanning can help to distinguish the nature of tumors, assess the systemic tumor load, define the scope of the lesion, and provide the metabolic status of various parts of the body. the application value of pet-ct related imaging features and metabolic information in ovarian cancer needs to be clarified. our team's previous study found that pet-ct related images and metabolic information showed certain advantages in predicting satisfactory resection of ovarian cancer, and the auc reached 0.85, which was better than the current ct image score and laparoscopic score. therefore, this project intends to conduct a multicenter retrospective study to evaluate the satisfactory tumor reduction rate of advanced ovarian cancer using pet-ct images to guide clinical practice and predict the prognosis of patients. at the same time, we will explore the molecular biological characteristics and clinical relevance of ovarian cancer through the combination of high-throughput sequencing genomics and radiomics.

Eligibility criteria:
inclusion criteria: * pathological type is epithelial ovarian cancer. * underwent primary debulking surgery at our hospital. * postoperative pathological staging is figo stage iib or above. * clinical, surgical, and pathological data of the patient are mostly complete. exclusion criteria: * pathological type is non-epithelial ovarian cancer. * underwent fertility-preserving surgery or palliative surgery. * presence of infection during pet/ct image acquisition. * concurrent other malignant tumors. * severe diseases of other major organs.

Keywords: ovarian cancer pet-ct image debulking prediction model
rapid dflc response predict chr in al amyloidosis

Conditions: Systemic AL Amyloidosis

Summary: light chain amyloidosis (al amyloidosis) is a rare plasma cell dyscrasia characterized by the deposition of insoluble amyloid fibrils in multiple organ systems. the treatment of amyloidosis primarily relies on anti-plasma cell therapy and supportive care. the application of anti-plasma cell therapy has significantly improved outcomes in patients with al amyloidosis. standard first-line therapy typically includes daratumumab, bortezomib, cyclophosphamide, and dexamethasone (dara-bcd), achieving a complete hematologic response in nearly 60% of patients.the depth and speed of the hematologic response are strongly correlated with organ response and overall survival. an early achievement of a complete hematologic response is particularly crucial in cases of al amyloidosis characterized by significant organ involvement. the median time to a hematologic response for the daratumumab based treatment is only 7-9 days. the retrospective data showed that the hematologic response in day 7 in cycle 1 (c1d7) may predict the complete hematologic response rate. in order to validate the conclusion, the investigator design this prospective study.


Eligibility criteria:
inclusion criteria: 1. diagnosis of systemic al amyloidosis; 2. daratumumab, bortezomib, dexamethasone used in treatment; 3. informed consent explained to, understood by and signed by the patient; 4. dflc ≥ 50 mg/l; exclusion criteria: 1. fulfill with the criteria of active multiple myeloma or active lymphoplasmacytic lymphoma; 2. presence of other tumors which is/are in advanced malignant stage and has/have systemic metastasis; 3. severe or persistent infection that cannot be effectively controlled; 4. presence of severe autoimmune diseases or immunodeficiency disease; 5. patients with active hepatitis b or hepatitis c (\[hbvdna+\] or \[hcvrna+\]); patients with hiv infection or syphilis infection; 6. any situations that the researchers believe will increase the risks for the subject or affect the results of the study.

Keywords: rapid dflc response daratumumab systemic al amyloidosis
partners in care with semi-structured support group

Conditions: Diabetes Mellitus, Type 2

Summary: the investigators are conducting a feasibility study using a randomized controlled trial (rct) design in which participants will receive the partners in care (pic) diabetes self-management intervention and then be randomized to either semi-structured social support or a standard follow-up control group. participants in the support groups will receive a culturally-tailored, semi-structured social support program delivered in a community setting by trained community peer educators and other health professionals (e.g., pharmacist). the investigators believe that the addition of a semi-structured social support component as a supplement to an evidence-based diabetes self-management intervention will improve diabetes self-care maintenance.


Eligibility criteria:
inclusion criteria: * self-reported native hawaiian, filipino, or other pacific islander ethnic background * adults age \>18 years of age * english-speaking * physician-diagnosed type 2 diabetes * baseline hemoglobin a1c \>8% exclusion criteria: * survival less than 6 months * planning to move out of the community during the intervention study period * pregnancy * any co-morbid condition (physical and mental disabilities) that would prevent the individual from participating in the intervention protocol (i.e., major psychiatric illness)

Keywords: diabetes self management support group semi structured support group
hot axios system japan post market survey

Conditions: Pancreatic Pseudocyst Infection; Pancreatic Pseudocyst; Walled Off Necrosis Infection; Walled Off Necrosis

Summary: to detect information of adverse events and device malfunctions under real world medical condition in japan.


Eligibility criteria:
inclusion criteria: * patient who received implant procedure using study device at japanese site. exclusion criteria: * na

Keywords: ppc won
integrated smartphone technology to alleviate malignant pain (i-stamp) testing

Conditions: Advanced Cancer; Pain

Summary: the purpose of the study is to evaluate if the smartphone app, i-stamp (integrated smartphone technology to alleviate malignant pain), helps participants with cancer pain manage symptoms and keep track of medications.

the goal of this study is to develop and refine i-stamp (integrated smartphone technology to alleviate malignant pain), an electronic health record-integrated mobile health (mhealth) application designed to support advanced cancer patients and care teams in pain management. the research study procedures include screening for eligibility, surveys, and interviews. it is expected that up to 73 participants will take part in this research study. activities 1-3 are non-interventional and will be used to collect data for application development. activity 4: this activity will be interventional and will be added with a future amendment.

Eligibility criteria:
inclusion criteria for participants (activities 1a, 2a, 3a): * age ≥ 21 years * current or previous diagnosis of advanced cancer * current or previous experience with cancer pain exclusion criteria for participants (activities 1a, 2a, 3a): * inability to understand, speak, or read english * any condition that would impede the patient's ability to complete study procedures such as visual impairment or significant cognitive impairment as determined by the participant's treating provider.

Keywords: advanced cancer pain management opioid pain management
multisensory stimulation in infants for eye examination

Conditions: Premature Retinopathy; Pain, Eye

Summary: this study aimed to evaluate the effects of multisensory stimulation on pain and physiological parameters resulting from rop examination in preterm newborns. it was planned as a randomized controlled trial. trying to reach 80 newborns in total. multisensory stimulation will be applied to the intervention group during the examination. in the control group, routine care will be applied during the examination.

preterm retinopathy may develop due to intubation in preterm newborns. therefore, this population undergoes eye examinations at regular intervals. this procedure is painful procedure for babies. nurses can apply interventions to reduce this pain. in this study, it was planned to apply multisensory stimulation to reduce the pain of the newborn. a randomized controlled trial and routine care were planned in the control group. neonatal pain will be assessed using the pipp scale.

Eligibility criteria:
inclusion criteria: * according to the registry, premature neonates with a gestational age of ≤ 32 weeks or newborns with a birth weight of \< 1500 g. * newborns undergoing a first-time eye exam to screen for retinopathy of prematurity. exclusion criteria: * newborns who need cpr during the examination. * newborns experience apnea during the examination.

Keywords: preterm infants multisensorial stimulation
polyethylene glycol (peg) versus sennosides study in opioid-induced constipation in cancer patients

Conditions: Constipation; Cancer

Summary: this is a study to compare the efficacy and tolerability of two laxatives for treatment of opioid-induced constipation in adult outpatients with cancer treated at the british columbia cancer pain and symptom management/palliative care clinics. each participating patient will be randomly assigned to one of two treatment groups.

one group will be started on a bowel protocol of escalating doses of sennosides, plus a dummy polyethylene glycol (lactose), and the other will receive dummy sennosides capsules (lactose) plus polyethylene glycol, with the same dosing protocol. after three weeks of one active treatment the patients will switch to the alternate active product and dummy preparation. the total duration for the study will be 6 weeks for each patient.

Eligibility criteria:
inclusion criteria: 1. adult patient (18 years and above) with diagnosis of cancer. 2. patient requires treatment or prevention of constipation. 3. patient is able to communicate effectively with staff. 4. expected prognosis more than 12 weeks. 5. on or starting opioid therapy exclusion criteria: 1. patient unable to take oral medication. 2. allergy or previous intolerance to peg or sennosides. 3. lactose intolerant. 4. contraindication to peg or sennosides. 5. known or suspected bowel obstruction or ileus. 6. colostomy or ileostomy. 7. inflammatory bowel disease. 8. hospitalisation expected within the study period. 9. patient unable to complete the study diary in english.

Keywords: constipation opioids cancer polyethylene glycol sennosides opioid therapy
vibrotactile coordinated reset for spasticity after spinal cord injury

Conditions: Spasticity, Muscle; Spinal Cord Injuries

Summary: the purpose of our study is to evaluate vibrotactile coordinated reset (vcr) and its effects on spasticity symptoms in incomplete spinal cord injured patients. vcr will be administered with a device called the stanford cr glove. vcr is expected to provide patients with a non-invasive alternative to the most widely used treatments such as oral baclofen and or deep brain stimulation. patients will be followed for three months and will be asked to come to the lab for clinical testing 4 times during this period. a total of 30 patients will be included in the study.


Eligibility criteria:
inclusion criteria: 1. age at the time of enrollment: any adult ages 18 and over 2. spinal cord injury: asia c or d injury at level c1-t1 3. duration of incomplete spinal cord injury minimum 1 years clinical/fundamental 4. spasticity with a of mas score \>3 present in upper extremities. 5. fluent in english 6. if patient is on medication that affects brain function or alters eeg activity, the patient must feel comfortable going off this medication prior to eeg recording. 7. appropriate social support if required during an off-medication state. 8. comfortable with technology; can use a computer, check email, and access the internet; can initiate and engage in a virtual meeting for training and monitoring purposes. 9. feels comfortable going off certain spasticity related medication during in-person study visits 10. lives in the united states exclusion criteria: 1. sensory deficits in palma manus resulting in missing inter digit discrimination of the fingertips. 2. any significant neuro-psychiatric problems, including acute confusional state, ongoing psychosis, or suicidal tendencies. 3. any current drug or alcohol abuse. 4. participation in another drug, device, or biologics trial concurrently or within the preceding 30 days. any other trial participation should be approved by the principal investigators. 5. pregnancy, breast-feeding or wanting to become pregnant. 6. physical limitations unrelated to spasticity that would affect motor ratings. 7. craniotomy 8. brain surgery 9. patient is unable to communicate properly with staff (i.e., severe speech problems) 10. medications that may affect relevant synaptic plasticity 11. concurrent botox treatment 12. a type of hairstyle that would impede the use of an eeg cap.
hemodynamic changes of patients receiving atenolol/bisoprolol

Conditions: Hypertension; Metabolic Syndrome

Summary: at hemodynamic level, the greater affinity of bisoprolol by the beta 1 receptor in theory could improve the peripheral arterial perfusion and could have a greater antihypertensive effect. at the same time, this could carry objectifiable improvements in the vascular tree, such as the level of arterial stiffness. this study attempts to mark the hemodynamic differences in the same individual with hypertension and metabolic syndrome who will be exposed to both drugs at different moments. parameters will be objectified with impedance cardiography, pulse wave velocity and central blood pressure assessment before and after taking each one of the drugs. the results will be compared to the baseline data and between themselves.


Eligibility criteria:
inclusion criteria: * hypertension * metabolic syndrome exclusion criteria: * severe hypertension \>180/110 * secondary hypertension * contraindication for betablockers * prior treatment with betablockers (up to one month before inclusion) * history of neoplastic disease * patients that do not sign informed consent
study of rv-39 in patients who also have asthma

Conditions: Asthma

Summary: this study will last up to 9 weeks. subjects will visit the clinic up to 14 times. certain clinic visits will include a physical examination, lung function tests, inflammatory cell analysis from nasal secretions and/or sputum, and blood draws. subjects will inhale an fda approved virus through their nose which is known to cause the common cold. all study related medications and medical examinations will be provided at no cost to the subject. the drugs used in this study are approved for the age group under study.


Eligibility criteria:
inclusion criteria: * have asthma for at least 3 months prior to the study. * have been using an allowed pre-study asthma therapy for at least 3 months prior to study. * demonstrate airway hyperresponsiveness following inhalation of bronchoconstrictor. * have a positive allergic status antibody test. exclusion criteria: * have a history of life-threatening asthma. * been hospitalized for asthma within the 24 months prior to the study. * have certain conditions that would make study participation unsafe. * the study doctor will evaluate other inclusion and exclusion criteria.

Keywords: rhinovirus asthma
long-term safety study of alogliptin used in combination with α-glucosidase inhibitor in participants with type 2 diabetes in japan

Conditions: Type 2 Diabetes Mellitus

Summary: the purpose of this study was to evaluate the long-term safety and efficacy of alogliptin and an α-glucosidase inhibitor administered once daily (qd) or three times daily (tid) for 40 consecutive weeks in participants who completed a phase 2/3 α-glucosidase inhibitor add on study.

both insulin hyposecretion and insulin-resistance are considered to be involved in the development of type 2 diabetes mellitus. takeda is developing syr-322 (alogliptin) for the improvement of glycemic control in patients with type 2 diabetes mellitus. alogliptin is an inhibitor of the dipeptidyl peptidase iv (dpp-iv) enzyme. dpp-iv is thought to be primarily responsible for the degradation of 2 peptide hormones released in response to nutrient ingestion. it is expected that inhibition of dpp-iv will improve glycemic control in patients with type 2 diabetes. "to evaluate the long-term safety and efficacy of alogliptin and an α-glucosidase inhibitor, this extension study was administered for 40 consecutive weeks (52 weeks from the start of treatment in the phase 2 dose-ranging study) to participants who completed a phase 2/3 α-glucosidase inhibitor add on study 322/cct-003 (nct01263483).

Eligibility criteria:
inclusion criteria: * had completed the phase 2 dose-ranging study (i.e., the subject had completed the study visit at week 12). exclusion criteria: * had clinical manifestations of hepatic impairment (e.g., an aspartate aminotransferase or alanine aminotransferase value 2.5 times or more of the upper reference limit at week 8 of treatment in the phase 2 dose-ranging study). * had clinical manifestations of renal impairment (e.g., a creatinine value of 2 mg/dl or more at week 8 of treatment in the phase 2 dose-ranging study).

Keywords: diabetes mellitus - type 2 diabetes mellitus drug therapy
functional status and quality of life in older patients undergoing robotic surgery for colorectal cancer

Conditions: Colorectal Surgery; Geriatric Assessment; Quality of Life

Summary: the present study evaluates prospectively the impact of robotic surgery on functional outcome and quality of life in older patients that are operated for colorectal cancer;


Eligibility criteria:
inclusion criteria: * patients ≥ 70 years with colorectal cancer * eligible for colorectal surgery after multidisciplinary board evaluation and patient consent exclusion criteria: * decline in cognitive function after geriatric evaluation * emergency surgery * life expectancy \< 3 months
lagra trial in laparoscopic cholecystectomy

Conditions: Regional Anesthesia Morbidity; Gallbladder Stone; Pain

Summary: this study investigated the effectiveness of a surgeon administered, laparoscopic guided, regional anaesthesia technique.

a prospective, double blind, randomised controlled trial was performed. consenting patients undergoing laparoscopic cholecystectomy were randomised, by envelope, to a laparoscopic guided 2-point blockade (subcostal transversus abdominis plane and rectus sheath) using either chirocaine® 2.5mg/ml (lagra) or 0.9% saline (placebo) after specimen extraction. primary endpoints were post-operative pain in the first 6 hours. secondary endpoints were analgesic/anti-emetic usage and day case and re-admission rates. data was analysed using graphpad prism (v7).

Eligibility criteria:
inclusion criteria: * patients undergoing laparoscopic cholecystectomy * asa i, ii or iii exclusion criteria: * patients that don't consent to be included * allergy to levobupivacaine
evaluation of the possible effect of inspiratory muscle training on inflammation markers and oxidative stress in childhood asthma

Conditions: Asthma in Children; Children, Adult

Summary: as inflammation and oxidative stress increase in asthma patients, the severity of symptoms and clinical findings increase. therefore, this study was planned to evaluate the possible effect of inspiratory muscle training (imt) on inflammation markers and oxidative stress in childhood asthma. the study included asthma patient; 35 routine medication, 35 drug therapy and inspiratory muscle training (imt), and 35 healthy total 105 children aged 8-17 years. demographic information and hemogram values were recorded. functional capacity was evaluated with the 6-minute walking test, quality of life pedsql, respiratory muscle strength oral pressure measuring device, respiratory function test, dyspnea severity with modified borg scale. c-reactive protein (crp), periostin, transforming growth factor-βeta (tgf-β), total antioxidant status (tas), total oxidant status (tos), oxidative stress index (osi) were analyzed. imt was given with a threshold imt device for 7 days/6 weeks at 30% of maximal inspiratory pressure, and then a second evaluation was made.


Eligibility criteria:
inclusion criteria: * have been diagnosed with asthma, * between the ages of 8-17, * no asthma attack, * cooperating with the study, * without cerebral palsy, mental retardation or any other major neurological diagnosis, * agreeing to participate in the study, * cases whose medication has not been changed for at least three weeks. exclusion criteria: * presence of kyphoscoliosis that may affect respiration, * having advanced postural alignment problem, * having mental problems, * having neuromuscular disease, * making changes in the medications used in the last three weeks, * presence of inflammatory diseases such as juvenile idiopathic arthritis.

Keywords: childhood asthma inspiratory muscle training inflammation